Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Oncogenesis
SJR: 0.946 SNIP: 0.503 CiteScore™: 2

ISSN Imprimer: 0893-9675
ISSN En ligne: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v16.i1-2.30
pages 13-24

Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia

Sarah Tasian
The Children's Hospital of Philadelphia
Mignon L. Loh
Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of California San Francisco, San Francisco, California

RÉSUMÉ

Recent genomic analyses of childhood and adult B-precursor acute lymphoblastic leukemia (ALL) samples have identified novel genetic alterations in essential lymphoid development and signal transduction pathways, providing insight into the pathogenesis of high-risk ALL associated with treatment failure. Particular advances have been made in unraveling the genetics of ALL associated with overexpression of the cytokine receptor-like factor 2 gene (CRLF2), which is frequently accompanied by simultaneous activating mutations in genes encoding Ikaros (IKZF1), Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), and/or the IL-7 receptor alpha chain (IL7RA). Children and adults with high-risk CRLF2-overexpressing ALL have high rates of relapse and dismal overall survival. Various groups have thus attempted to characterize the biochemical consequences of these genetic lesions via preclinical models with the goal of identifying targets for new therapies. These studies provide early data suggesting the promise of signal transduction inhibitors (STIs) of the JAK/STAT and PI3K pathways for CRLF2-overexpressing ALL. Additional research efforts continue to elucidate these aberrant signaling networks to provide rationale for bringing STIs into the clinic for these high-risk patients. This review highlights the current knowledge of the incidence, prognostic significance, and biology of CRLF2-overexpressing ALL and future directions for development of targeted therapies.


Articles with similar content:

Ikaros and Tumor Suppression in Acute Lymphoblastic Leukemia
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 1-2
Sinisa Dovat, Kimberly J. Payne
Epigenetic Targets of Arsenic: Emphasis on Epigenetic Modifications During Carcinogenesis
Journal of Environmental Pathology, Toxicology and Oncology, Vol.34, 2015, issue 1
Donghern Kim, Yuanqin Yin, Zhuo Zhang, Young-Ok Son, Poyil Pratheeshkumar, Ram Vinod Roy, Rakesh D, Lei Wang, Sasidharan Padmaja Divya, John Andrew Hitron, Xianglin Shi
Functional Implications of BRCA1 for Early Detection, Prevention, and Treatment of Breast Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.16, 2006, issue 3
Alvaro N. A. Monteiro, Virna Dapic
Oncogenic Potential of Yin Yang 1 Mediated Through Control of Imprinted Genes
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 3-4
Michelle M. Thiaville , Joomyeong Kim
Point Mutations in the AML1/RUNX1 Gene Associated with Myelodysplastic Syndrome
Critical Reviews™ in Eukaryotic Gene Expression, Vol.15, 2005, issue 3
Yuka Harada, Hironori Harada